Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Revenue (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed Revenue for 9 consecutive years, with $1.0 million as the latest value for Q1 2026.

  • For Q1 2026, Revenue changed N/A year-over-year to $1.0 million; the TTM value through Mar 2026 reached -$34000.0, changed N/A, while the annual FY2025 figure was $10.8 million, N/A changed from the prior year.
  • Revenue hit $1.0 million in Q1 2026 for Crescent Biopharma, up from -$1.1 million in the prior quarter.
  • Across five years, Revenue topped out at $1.0 million in Q1 2026 and bottomed at -$1.1 million in Q2 2025.
  • Average Revenue over 3 years is $13666.7, with a median of $75000.0 recorded in 2022.
  • On a YoY basis, Revenue climbed as much as 52716.9% in 2022 and fell as far as 52716.9% in 2022.
  • Crescent Biopharma's Revenue stood at $75000.0 in 2022, then tumbled by 1530.67% to -$1.1 million in 2025, then soared by 196.83% to $1.0 million in 2026.
  • According to Business Quant data, Revenue over the past three periods came in at $1.0 million, -$1.1 million, and $75000.0 for Q1 2026, Q2 2025, and Q2 2022 respectively.